2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, Tsai T, Gordon K, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl M. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. The Lancet 2023, 402: 1541-1551. PMID: 37738999, DOI: 10.1016/s0140-6736(23)01378-8.Peer-Reviewed Original ResearchConceptsPhysician Global Assessment scoreGPP flaresGlobal assessment scoreFlare preventionDose-response relationshipPrimary endpointAssessment scoresPhase 2b trialPustular psoriasis flarePlacebo-controlled trialReceptor monoclonal antibodyEligible study participantsQuality of lifeDose-response curveSubcutaneous placeboPlacebo groupWeek 48Pustular psoriasisPrimary outcomePsoriasis flareTreatment armsPatient groupHypersensitivity reactionsPatient morbiditySpesolimab
2019
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater E, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal Of The American Academy Of Dermatology 2019, 82: 161-201. PMID: 31703821, DOI: 10.1016/j.jaad.2019.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAnthralinBiological ProductsCalcineurin InhibitorsCardiovascular DiseasesChildChild, PreschoolCoal TarComorbidityCyclosporineDermatologic AgentsDyslipidemiasEvidence-Based MedicineHumansInfantInfant, NewbornInflammatory Bowel DiseasesInsulin ResistanceMental HealthMetabolic SyndromeMethotrexateNicotinic AcidsObesityPhotochemotherapyPsoriasisRetinoidsConceptsPediatric patientsDermatology–National Psoriasis Foundation guidelinesTreatment of psoriasisImportant clinical questionsEvidence-based recommendationsJoint American AcademyPsoriasis managementInflammatory diseasesFoundation guidelinesClinical questionsPatientsAmerican AcademyPsoriasisProvider interactionsGuideline sectionsUnique physiologyGuidelinesPharmacokineticsDiseaseCareMultisystem
2017
Clinical trials: Kids are not just little people
Naka F, Strober B, Shahriari M. Clinical trials: Kids are not just little people. Clinics In Dermatology 2017, 35: 583-593. PMID: 29191349, DOI: 10.1016/j.clindermatol.2017.08.008.Peer-Reviewed Original Research
2016
Psoriasis in adults and children: Kids are not just little people
de Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clinics In Dermatology 2016, 34: 717-723. PMID: 27968931, DOI: 10.1016/j.clindermatol.2016.07.006.Peer-Reviewed Original ResearchConceptsPediatric psoriasisPediatric populationLimited therapeutic armamentariumPrimary care providersCommon skin disorderAdult psoriasisYounger patientsTherapeutic armamentariumTreatment optionsSchool-aged childrenAppropriate treatmentCare providersPsoriasisSkin disordersIncurable diseasePsychosocial ramificationsPatientsAge childrenChildrenInherent risksPresentationChronicInfantsTherapyPopulationTreatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2012
Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link.
Marmon S, De Souza A, Strober B. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatology Online Journal 2012, 18: 13. PMID: 22747937, DOI: 10.5070/d305m5f4bx.Peer-Reviewed Original ResearchConceptsDown syndromeSerum levelsIFN-gammaChronic plaque psoriasisPotential pathophysiologic linksHigher serum levelsCases of patientsProduction of cytokinesTumor necrosis factorTh1 lineage cellsPathophysiologic linkPlaque psoriasisTh17 cellsTh17 pathwayPatient populationIL-2Healthy controlsNecrosis factorGreater prevalencePsoriasisSyndromeIFN systemPatientsLineage cellsCells
2009
A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach
Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal Of The American Academy Of Dermatology 2009, 61: s1-s46. PMID: 19527820, DOI: 10.1016/j.jaad.2009.03.017.Peer-Reviewed Original ResearchConceptsTreatment optionsSevere psoriasisAvailable evidence-based dataHistory of malignancyEfficacious treatment optionBreast-feeding womenMedical treatment optionsSystemic psoriasis therapiesEvidence-based dataDelphi consensus approachLatent tuberculosisPsoriatic diseaseLiver diseasePsoriasis therapyHealthy patientsTreatment recommendationsClinical trialsCardiovascular diseaseConsensus panelViral infectionPatientsOptimum managementDisease statesMedical evidenceDiseaseMethotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
Kalb R, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. Journal Of The American Academy Of Dermatology 2009, 60: 824-837. PMID: 19389524, DOI: 10.1016/j.jaad.2008.11.906.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisUse of methotrexateLiver biopsyNational Psoriasis Foundation Medical BoardAppropriate patient selectionNational Psoriasis FoundationEvidence-based studiesMedical boardsMethotrexate therapyPatient selectionRheumatoid arthritisTreatment optionsHepatic fibrosisRisk factorsConsensus conferencePsoriasisSide effectsEffective drugsLast guidelinesMethotrexateValuable optionTreatmentBiopsyTask ForceReport
2005
Off-Label Dermatologic Uses of Anti-TNF-a Therapies
Alexis A, Strober B. Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal Of Cutaneous Medicine And Surgery 2005, 9: 296-302. PMID: 16699906, DOI: 10.1007/s10227-005-0110-7.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticChildChild, PreschoolChi-Square DistributionEtanerceptFemaleHumansImmunoglobulin GInfantInfliximabMalePsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorSkin DiseasesTime FactorsTumor Necrosis Factor-alphaConceptsDermatologic usesTNF inhibitorsDermatologic diseasesSneddon-Wilkinson diseaseInflammatory skin diseaseSmall case seriesNecrobiosis lipoidica diabeticorumPityriasis rubra pilarisMethodsA MEDLINE searchNumerous inflammatory skin diseasesIndividual case reportsApthous stomatitisBehçet's diseaseEosinophilic fasciitisSAPHO syndromeCase seriesCicatricial pemphigoidCrohn's diseaseMulticentric reticulohistiocytosisImmunomodulatory roleProinflammatory cytokinesCase reportLabel useMEDLINE searchSkin diseases